MicroRNAs (miRNAs) are endogenous small RNAs that play an important role in various physiological processes by downregulating target genes. Recently, plasma miRNAs have been investigated as biomarkers for various diseases. In this study, miRNA array analysis in various tissues showed that miR-124 is almost exclusively expressed in the central nervous system and neuronal cells, suggesting that it might be useful as a potential biomarker for neurological diseases. We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat. Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after MCAO introduction. Thus, plasma concentration of miR-124 provides a promising candidate biomarker for early detection of cerebral infarction.
MicroRNAs (miRNAs) are endogenous small RNAs of approximately [18] [19] [20] [21] [22] [23] nucleotides that bind to the 3′-untranslated region of messenger RNAs of protein-coding genes to downregulate their expression (2, 4) . miRNAs play an important role in various physiological and pathological processes (9, 20) . So far, more than 500 human miRNAs have been identified (14) , and they are expressed in a tissue-or cell-specific manner (22) . Most human protein-coding genes are thought to be targeted by miRNAs (11, 24 ) that appear to function as rheostats to fine-tune protein output (3, 29) . Recently, the presence of miRNA in various body fluids has been reported (7, 8, 13) . The concentrations of miRNAs in serum or plasma have been reported to be stable, reproducible, and consistent among individuals (7) . More than 90 species of miRNAs have been detected in human sera by using next-generation sequencing (7) . miRNAs in the plasma appear to exist in 2 separate fractions, namely in a free RISC (RNA-induced silencing complex)-embedded form, and in exosomes and/or microparticles (1, 15, 18) . We have recently reported that plasma concentrations of miR-208, a rat myocardium-specific miRNA, are significantly increased after isoproterenol-induced myocardial injury (18) . Moreover, the plasma concentrations of miR-499, a human myocardium-specific miRNA, are increased in patients with myocardial infarction (1). Other groups have also reported that plasma miRNAs are sensitive and specific biomarkers for various tissue injuries and pathological conditions (23, 26, 30, 31) . In this study, we test the hypothesis that plasma concentration of brain-specific miRNA is a promising biomarker for cerebral infarction.
MATERIALS AND METHODS
Identification of brain specific miRNAs by microRNA array analysis. Human RNAs from various tissues were obtained from Clontech-Takara (Kyoto). In addition, human primary cultured cells (neurons, astrocytes, oligodendrocyte precursors, microglia, brain acid (EDTA) (Terumo Co., Tokyo, Japan) from the right or left jugular vein from each rat, and plasma was isolated by centrifugation at 1,600 g for 15 min at room temperature. Total RNA of the plasma was then isolated using the mirVana PARIS kit (Ambion, Austin, TX, USA) as described previously (18) . miRNA concentration was measured using the TaqMan microRNA real-time reverse transcriptionpolymerase chain reaction (RT-PCR) kit (6) (Applied Biosystems) as described previously (18) . The ABI Prism 7700 Sequence Detection System (Applied Biosystems) was used for amplification and detection. The C T value was obtained from the amplification plot with the aid of the SDS software (Applied Biosystems). The C T value of a known amount of synthetic miR-124 (Integrated DNA Technologies, Coralville, IA, USA) was used as a reference to determine the absolute amounts of miR-124 in plasma (data not shown). Note that the detection limit of miR-124 in this assay was at 0.01 amol/100 μL plasma (60 copies/μL plasma), which corresponded to a C T value of approximately 31.5.
Statistical analysis.
Data are presented as the mean ± SD. Statistical analysis was performed by multiple analyses of variance (MANOVA) and a regression analysis using JMP statistical analysis package (SAS Institute, Cary, NC).
RESULTS

Identification of brain-specific miRNA
In order to identify miRNA(s) specifically expressed in brain tissues, total RNAs in the cerebrum, cerebellum, heart, lung, liver, kidney, colon, skin, skeletal muscle, and pancreas were subjected to a miRNA array (Fig. 1A) . Out of the total of 671 miRNAs analyzed, 389 and 395 miRNAs were significantly detected in the cerebrum and cerebellum, respectively. Hierarchical clustering analysis showed that the expression of 13 miRNAs, out of the ones significantly detected in the cerebrum and cerebellum, was specific to these brain tissues. miR-124 showed the strongest signal, followed by miR-219 and miR-346. miRNA array analyses data will be provided upon request. The expression levels of these 3 miRNA were validated by real-time RT-PCR (Fig. 1B) . A considerable amount of miR-346 was detected in almost all of tissues. A certain amount of miR-219 was also detected in coronary artery endothelial cells, and coronary artery smooth muscle cells in addition to its expression in brain tissues. On the other hand, microvascular endothelial cells, brain vascular pericytes, and perineurial cells) were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). The validity of each cellular phenotype was confirmed using specific cellular marker proteins. The expression profiling of miRNA in these samples was performed using the ABI TaqMan MicroRNA Array kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. SDS software v2.3 and RQ manager v1.2 (Applied Biosystems) were used to obtain the comparative threshold cycle (C T ) value. The relative expression level of miRNA (2 35-CT or 2 45-CT ) was then calculated and normalized by Z-formation (5) . Hierarchical clustering analysis with complete linkage was performed using the Cluster and Treeview software packages (10) .
Rat middle cerebral artery occlusion model. Male
Wistar rats (weighing 390-430 g) were purchased from Japan SLC (Shizuoka, Japan). The rats were housed in a temperature-controlled room on a 12 h light/12 h dark cycle, and fed standard rat chow (Clea Japan, Tokyo, Japan) and tap water ad libitum. The present study was conducted in accordance with the guidelines of the National Cerebral and Cardiovascular Center for the care and use of experimental animals and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adequate measures were taken to minimize pain and discomfort. Permanent middle cerebral artery occlusion (MCAO) was induced in Wistar rats as described previously (12, 25) with modifications. In brief, rats were anesthetized with sodium pentobarbital (25 mg/ kg body weight, i.p.), and a 0.2-0.3 mm diameter nylon suture was inserted in the right common carotid artery. The nylon suture was further inserted through the right internal carotid artery until it reached a position where the middle cerebral artery could be occluded. Brain infarct size was estimated by 2,3,5-triphenyltetrazolium chloride (TTC) staining as described previously (12) with modifications. In brief, the brains were sectioned into five 2-mm thick slices and stained in 1% TTC at 37°C for 30 min. Each infarct area was measured using the Image J software (National Institutes of Health, Bethesda, MD), and the infarct size as a percentage of the total brain volume was calculated.
Quantification of miRNA by real-time reverse transcription-polymerase chain reaction. Blood was collected in tubes containing ethylenediaminetetraacetic in sham-operated rats were below the limit of detection. miR-451 is known to be abundantly present in red blood cells (28) , and is detected in EDTA plasma preparations. Ribosomal 5S rRNA is also detected in rat plasma (18) . We therefore analyzed the levels of miR-451 and 5S rRNA as controls. No significant changes in either miR-451 or 5S rRNA concentrations were observed in both the control and the MCAO model, suggesting that the elevation of the plasma concentrations of miR-124 is specific marker for cerebral infarction (Fig. 3B) . miR-124 was detected almost exclusively in brain tissues. miR-124 was widely expressed in the central nervous system, and the strongest signal was obtained from the cerebellum (Fig. 2) . In cultured primary cells related to the central nervous system, miR-124 was exclusively expressed in neuronal cells. Given the specificity of its expression, we selected miR-124 for further investigation as the candidate miRNA biomarker for cerebral infarction.
Plasma levels of miR-124 in the rat MCAO model
We confirmed that similar to miR-124 specificity in the human central nervous system, the basal expression of miR-124 was confined to the rat central nervous system including cerebrum, cerebellum, and spinal cord (data not shown). We then assessed the plasma level of miR-124 in the rat MCAO model. The plasma was obtained before and 6, 12, 24, and 48 h after the occlusion (Fig. 3A) . The plasma concentration of miR-124 was significantly increased at 6 h in the MCAO model, and was still significantly elevated at 48 h. Plasma concentrations of miR-124 
Correlation between the cerebral infarct size and plasma miR-124 levels
We next compared cerebral infarct sizes and plasma miR-124 concentrations. Plasma miR-124 concentrations were obtained at 48 h after MCAO introduction. The rats were then sacrificed, and the area of brain infarction was determined by TTC staining (Fig. 4A) . A total of 13 rats that underwent MCAO were examined, and an average brain area of 19.4 ± 5.3 (%) showed negative staining (infarct area). Linear regression analysis between the infarct size and plasma miR-124 level showed no correlation (Fig. 4B) .
DISCUSSION
In the present study, we determined miRNA profiles in the central nervous system, and found that miR-124 and miR-219 were almost exclusively expressed in the central nervous system. Especially, miR-124 appeared to be specifically expressed in neuronal cells (Fig. 2) . Given its specificity, we investigated whether plasma concentrations of miR-124 could be used as a biomarker for cerebral infarction. We observed that plasma levels of miR-124 significantly increased at 6 h after MCAO introduction, and remained elevated until 48 h after the initial introduction (Fig. 3) . In agreement with our data, Laterza et al. (23) reported that plasma concentrations of miR-124 are increased at 24 h after introduction of MCAO. Collectively, these findings support the notion that plasma miR-124 can be a biomarker for cerebral infarction. However, no significant correlation between infarct size and plasma miR-124 concentrations was observed in the MCAO model. There might be several reasons for the lack of such a correlation. Brain edema after infarction may prevent swift release of miR-124 from necrotic cells into circulating blood. Moreover, the degree of destruction of the blood brain barrier, which is a prerequisite for miR-124 release into circulating blood, may not correlate with the infarct size. An accurate and reliable blood biomarker for stroke is currently lacking, although its availability has long been desired for the purpose of early diagnosis and risk prediction. At present, the diagnosis of brain infarction relies on imaging techniques such as magnetic resonance imaging. Several protein markers have been suggested to be elevated on cerebral infarction. However, neither are these markers detected in the early phase of stroke nor are they specific for brain injury. For example, the serum concentration of S100B, a subunit of the S100 protein, is known to be significantly increased in stroke (17, 27) , possibly due to disruption of the bloodbrain barrier (21) . Moreover, the increase in S100B is correlated with infarct size (19) . However, S100B is also expressed in other tissues or cells, such as melanocytes and adipocytes (21) , and has been reported to be increased by various tumors (16) . As previously mentioned, plasma miRNAs appear in 2 separate fractions: in a free RISC-embedded form and/or in exosomes. Necrotic cells are thought to release RISC-embedded miRNAs in the cytoplasm into the circulating blood due to disruption of cellular membranes; therefore, plasma concentrations of various miRNAs are perceived as useful biomarkers to diagnose the presence of necrotic tissues or cells. However, the biological significance of miRNAs in exosomes remains to be determined, and awaits further investigation. We found the miR-124 was specifically expressed in the central nervous system, and elevated due to brain infarction in a rat model. Furthermore, we were able to accurately and readily determine the plasma levels of miR-124 by real-time RT-PCR. Thus, plasma miR-124 has the potential to be an excellent candidate biomarker for cerebral infarction. However, the clinical significance of plasma miR-124 concentration in the diagnosis of cerebral infarction and other diseases related to central nervous system needs to be further investigated and assessed in clinical settings.
